Charles Schwab Investment Management Inc. Boosts Stock Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Charles Schwab Investment Management Inc. lifted its position in ImmunityBio, Inc. (NASDAQ:IBRX) by 0.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 1,276,673 shares of the company’s stock after purchasing an additional 10,692 shares during the quarter. Charles Schwab Investment Management Inc.’s holdings in ImmunityBio were worth $3,268,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Stephens Inc. AR acquired a new position in ImmunityBio during the fourth quarter valued at $26,000. Captrust Financial Advisors acquired a new position in shares of ImmunityBio in the 3rd quarter valued at about $41,000. New York State Common Retirement Fund lifted its holdings in shares of ImmunityBio by 62.8% in the 4th quarter. New York State Common Retirement Fund now owns 32,418 shares of the company’s stock valued at $83,000 after buying an additional 12,500 shares during the period. Virtu Financial LLC purchased a new stake in shares of ImmunityBio in the third quarter worth about $51,000. Finally, China Universal Asset Management Co. Ltd. grew its holdings in ImmunityBio by 10.3% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 147,754 shares of the company’s stock worth $378,000 after acquiring an additional 13,788 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have commented on IBRX shares. HC Wainwright restated a “buy” rating and issued a $8.00 price objective on shares of ImmunityBio in a research report on Thursday, March 13th. BTIG Research began coverage on shares of ImmunityBio in a research report on Friday, January 10th. They set a “buy” rating and a $6.00 price target on the stock. Finally, D. Boral Capital reiterated a “buy” rating and issued a $30.00 price objective on shares of ImmunityBio in a research report on Thursday, March 13th. One investment analyst has rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $12.19.

ImmunityBio Price Performance

Shares of IBRX stock opened at $3.36 on Friday. ImmunityBio, Inc. has a 1-year low of $2.28 and a 1-year high of $10.53. The company has a market cap of $2.87 billion, a price-to-earnings ratio of -3.65 and a beta of 0.82. The stock has a 50 day simple moving average of $3.12 and a 200-day simple moving average of $3.60.

ImmunityBio (NASDAQ:IBRX) last posted its quarterly earnings data on Monday, March 3rd. The company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.11. The company had revenue of $7.55 million for the quarter, compared to analyst estimates of $8.74 million. Analysts anticipate that ImmunityBio, Inc. will post -0.92 earnings per share for the current fiscal year.

About ImmunityBio

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.